Skip to main content

ATP7b Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NB100-361

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Validated:

Human, Rat, Mouse (Negative)

Cited:

Human, Rat

Applications

Validated:

Immunocytochemistry/ Immunofluorescence, Western Blot

Cited:

Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Concentration

1 mg/ml

Product Specifications

Immunogen

A synthetic peptide made to an internal sequence near the C-terminus of human ATP7b. [UniProt# P35670]

Reactivity Notes

Does not appear to react in mouse species.

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Theoretical MW

165 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for ATP7b Antibody

Immunocytochemistry/ Immunofluorescence: ATP7b Antibody [NB100-361]

Immunocytochemistry/ Immunofluorescence: ATP7b Antibody [NB100-361]

Immunocytochemistry/Immunofluorescence: ATP7b Antibody [NB100-361] - Caco-2 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-ATP7b Antibody NB100-361 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.
ATP7b Antibody

Western Blot: ATP7b Antibody [NB100-361] -

Western Blot: ATP7b Antibody [NB100-361] - Effects & mechanism of action of CASIN on melphalan-resistant MM cells. (A) CASIN reduces Cdc42 activity (Cdc42-GTP) but not Rac1 activity (Rac1-GTP). Melphalan-sensitive MM cells (S) were treated with Vehicle or CASIN (5 μM) for 8 h. Cdc42 & Rac1 activities were measured using pull-down assay. (B) CASIN (5 μM) inhibits proliferation of both S & melphalan-resistant (LR5) MM cells. **P < 0.01 vs. S-Vehicle; ##P < 0.01 vs. LR5-Vehicle. (C) CASIN (5 μM) preferentially causes apoptosis of melphalan-resistant MM cells. S & LR5 cells were treated with or without CASIN or melphalan (Mel, 25 μM) or both for 2 days. Annexin V+ cells were analyzed using flow cytometry. **P < 0.01. (D–F) Mechanism of action of CASIN on melphalan-resistant MM cells. (D) Cdc42 activity & expression are increased in LR5 cells compared to that in S cells. Cdc42 activity was measured using pull-down assay. beta-Actin was used as loading control. Vertical lines indicate the gel lanes being switched in position from the original blots. (E) CASIN (5 μM) decreases melphalan-induced FANCD2 mono-ubiquitination (Ub-FANCD2) in LR5 but not in S cells. S & LR5 cells were treated with or without CASIN, Mel (25 μM), or both for 16 h. FANCD2 was detected using western blotting. beta-Actin was used as loading control. (F) CASIN sensitizes melphalan-resistant but not -sensitive MM cells to melphalan-induced DNA damage. gamma H2A histone family member X-positive ( gammaH2AX+) cells were detected using flow cytometry. **P < 0.01. Error bars represent means ± SD of triplicates & data are representative of three independent experiments. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31632904), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Applications for ATP7b Antibody

Application
Recommended Usage

Immunocytochemistry/ Immunofluorescence

1:10-1:2000

Western Blot

1:1000
Application Notes
This ATP7b antibody is useful for Immunocytochemistry/Immunofluorescence and Western blot. By WB, this antibody recognizes a band at 165 kDa, representing ATP7b. This antibody also recognizes a band at ~220 kDa. This antibody may work on endogenous protein in immunohistochemistry, but it has only been tested on transfected ovarian carcinoma cells at a 1:500 dilution. However, NB100-360 may demonstrate less background for this assay.

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

PBS

Preservative

0.02% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C. Avoid freeze-thaw cycles.

Background: ATP7b

ATP7b (copper-transporting P-type adenosine triphosphatase) is also called copper-transporting ATPase 2 or Wilson disease-associated protein and is involved in copper export out of the cells, such as the efflux of hepatic copper into the bile. ATP7b is a monomeric protein that interacts with COMMD1/MURR1, DCTN4 (in copper-dependent manner) and ATOX1. Predominantly localized in the trans-Golgi network (TGN), ATP7b is most abundantly expressed in liver, kidney and the brain tissues (isoform 2 is expressed in cytoplasm of brain cells but not in liver). Isoform 1 is proteolytically cleaved at N-terminus to produce the WND/140 kD form which is found in mitochondrions of hepatocytes as well as other tissue/cell types. Defects in ATP7B have been linked to Wilson disease (WD), an autosomal recessive disorder of copper metabolism, wherein, copper cannot be incorporated into hepatic ceruloplasmin and cannot be excreted from the liver into the bile.

Alternate Names

ATPase, Cu(2+)- transporting, beta polypeptide, ATPase, Cu++ transporting, beta polypeptide, Copper pump 2, copper-transporting ATPase 2, EC 3.6.3, EC 3.6.3.4, PWD, WC1, WD, Wilson disease-associated protein, WNDATPase, Cu++ transporting, beta polypeptide (Wilson disease)

Gene Symbol

ATP7B

Additional ATP7b Products

Product Documents for ATP7b Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for ATP7b Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...